All material subject to strictly enforced copyright laws. © 2022 Euromoney Institutional Investor PLC group
Corporate Bonds

Bayer’s $7bn acquisition bond a $27bn hit in worst week of 2014

Bayer 230x150

Bayer, the German pharmaceutical and chemical company, braved the toughest credit market conditions of 2014 this week to complete its biggest bond deal, as investors lost their appetite for risk.

Unlock this article.

The content you are trying to view is exclusive to our subscribers.

To unlock this article:

Take a Free Trial or Login
We use cookies to provide a personalized site experience.
By continuing to use & browse the site you agree to our Privacy Policy.
I agree